cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study

CompletedOBSERVATIONAL

Enrollment

1,717

Participants

Timeline

Start Date

May 16, 2017

Primary Completion Date

July 13, 2017

Study Completion Date

July 13, 2017

Conditions

Arrhythmias, CardiacAtrial Fibrillation and FlutterTachycardia, SupraventricularCardiac Failure

Interventions

DRUG

L02 (sex hormones used in treatment of neoplastic diseases) and G03 (sex hormones)

Androgen-deprivation therapies including L02 (sex hormones used in treatment of neoplastic diseases), and G03 (sex hormones)

Trial Locations (1)

Centre Régional de Pharmaco-vigilance - Paris, Pitié-Salpétrière, Paris

All Listed Sponsors

lead

Groupe Hospitalier Pitie-Salpetriere

OTHER

NCT03243604 - cARdiotoxicity Profile of aBIraTeRone in prostAte Cancer : a pharmacoviGilancE Study | Biotech Hunter | Biotech Hunter